KMI169

KMI169 is a potent and selective inhibitor targeting lysine methyl-transferase (KMT9) (IC50 = 0.05 μM, Kd = 0.025 μM) . KMI169 functions as a bi-substrate inhibitor targeting the cofactor S-5’-adenosyl-L-methionine (SAM) and substrate binding pockets of KMT9. KMI169 can downregulate target genes involved in cell cycle regulation and impair proliferation of tumor cells by inhibiting KMT9. KMI169 is a valuable tool to probe cellular KMT9 functions and can be research for combating diseases including prostate, lung, colon, and invasive bladder cancer[1][2].

Product Specifications

UNSPSC

12352005

Target

Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/kmi169.html

Purity

98.00

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

NC1=C2C(C3=NN(C=C3Cl)CC4=CC=CC=C4)=CN([C@@H]5C[C@H](C6=CC(CN7CCC7)=CC=C6)[C@@H](O)[C@H]5O)C2=NC(Cl)=N1

Molecular Formula

C31H31Cl2N7O2

Molecular Weight

604.53

References & Citations

[1]Wang S, et al. Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity. Nat Commun. 2024 Jan 2;15 (1) :43.|[2]Totonji, S., et., (2024) . Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer. Cancers, 16 (8), 1532.